EdgarLookup

SMITH MICRO SOFTWARE, INC. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that SMITH MICRO SOFTWARE, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-168.9%
Profit Margin
Net income ÷ revenue
-117.4%
Return on Assets
Net income ÷ assets
-15.5%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $17.36M Mar 5, 2026
FY2025 Dec 31, 2024 $20.56M Mar 5, 2026
FY2024 Dec 31, 2023 $40.86M Mar 12, 2025
FY2023 Dec 31, 2022 $48.51M Feb 26, 2024
FY2022 Dec 31, 2021 $58.42M Mar 23, 2023
FY2020 Dec 31, 2020 $12.42M Mar 8, 2021
FY2020 Sep 30, 2020 $12.63M Mar 8, 2021
FY2020 Jun 30, 2020 $12.93M Mar 8, 2021
FY2020 Mar 31, 2020 $13.32M Mar 8, 2021
FY2020 Dec 31, 2019 $12.28M Mar 8, 2021

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $5.73M Mar 30, 2018
FY2017 Sep 30, 2017 $5.80M Mar 30, 2018
FY2017 Jun 30, 2017 $5.86M Mar 30, 2018
FY2017 Mar 31, 2017 $5.58M Mar 30, 2018
FY2017 Dec 31, 2016 $7.08M Mar 30, 2018
FY2017 Sep 30, 2016 $6.48M Mar 30, 2018
FY2017 Jun 30, 2016 $7.46M Mar 30, 2018
FY2017 Mar 31, 2016 $7.21M Mar 30, 2018
FY2016 Dec 31, 2015 $10.01M Mar 10, 2017
FY2016 Sep 30, 2015 $9.59M Mar 10, 2017

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $12.86M Mar 5, 2026
FY2025 Dec 31, 2024 $14.43M Mar 5, 2026
FY2024 Dec 31, 2023 $30.30M Mar 12, 2025
FY2023 Dec 31, 2022 $34.30M Feb 26, 2024
FY2022 Dec 31, 2021 $45.72M Mar 23, 2023
FY2020 Dec 31, 2020 $10.99M Mar 8, 2021
FY2020 Sep 30, 2020 $11.30M Mar 8, 2021
FY2020 Jun 30, 2020 $11.66M Mar 8, 2021
FY2020 Mar 31, 2020 $12.15M Mar 8, 2021
FY2020 Dec 31, 2019 $11.25M Mar 8, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($29.33M) Mar 5, 2026
FY2025 Dec 31, 2024 ($48.70M) Mar 5, 2026
FY2024 Dec 31, 2023 ($24.40M) Mar 12, 2025
FY2023 Dec 31, 2022 ($29.28M) Feb 26, 2024
FY2022 Dec 31, 2021 ($31.04M) Mar 23, 2023
FY2020 Dec 31, 2020 $580.0K Mar 8, 2021
FY2020 Sep 30, 2020 $161.0K Mar 8, 2021
FY2020 Jun 30, 2020 $1.38M Mar 8, 2021
FY2020 Mar 31, 2020 $2.05M Mar 8, 2021
FY2020 Dec 31, 2019 $3.67M Mar 8, 2021

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($29.01M) Mar 5, 2026
FY2025 Dec 31, 2024 ($49.39M) Mar 5, 2026
FY2024 Dec 31, 2023 ($18.06M) Mar 12, 2025
FY2023 Dec 31, 2022 ($30.93M) Feb 26, 2024
FY2022 Dec 31, 2021 ($30.94M) Mar 23, 2023
FY2020 Dec 31, 2020 ($12.0K) Mar 8, 2021
FY2020 Sep 30, 2020 $196.0K Mar 8, 2021
FY2020 Jun 30, 2020 $1.38M Mar 8, 2021
FY2020 Mar 31, 2020 $1.96M Mar 8, 2021
FY2020 Dec 31, 2019 $3.63M Mar 8, 2021

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $10.72M Mar 5, 2026
FY2025 Dec 31, 2024 $14.09M Mar 5, 2026
FY2024 Dec 31, 2023 $17.15M Mar 12, 2025
FY2023 Dec 31, 2022 $29.39M Feb 26, 2024
FY2022 Dec 31, 2021 $26.20M Mar 23, 2023
FY2021 Dec 31, 2020 $17.77M Mar 11, 2022
FY2020 Dec 31, 2019 $11.68M Mar 8, 2021
FY2019 Dec 31, 2018 $8.60M Mar 13, 2020
FY2018 Dec 31, 2017 $8.95M Mar 27, 2019
FY2017 Dec 31, 2016 $15.91M Mar 30, 2018

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($7.19M) Mar 5, 2026
FY2025 Dec 31, 2024 ($14.30M) Mar 5, 2026
FY2024 Dec 31, 2023 ($6.97M) Mar 12, 2025
FY2023 Dec 31, 2022 ($19.26M) Feb 26, 2024
FY2022 Dec 31, 2021 ($12.92M) Mar 23, 2023
FY2021 Dec 31, 2020 $7.92M Mar 11, 2022
FY2020 Dec 31, 2019 $9.99M Mar 8, 2021
FY2019 Dec 31, 2018 ($2.87M) Mar 13, 2020
FY2018 Dec 31, 2017 ($7.42M) Mar 27, 2019
FY2013 Dec 31, 2013 ($16.57M) Mar 7, 2014

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $88.0K Mar 5, 2026
FY2025 Dec 31, 2024 $20.0K Mar 5, 2026

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $24.97M Mar 5, 2026
FY2025 Dec 31, 2024 $48.05M Mar 5, 2026
FY2024 Dec 31, 2023 $85.58M Mar 12, 2025
FY2023 Dec 31, 2022 $103.58M Feb 26, 2024
FY2022 Dec 31, 2021 $114.51M Mar 23, 2023
FY2021 Dec 31, 2020 $72.90M Mar 11, 2022
FY2020 Dec 31, 2019 $61.20M Mar 8, 2021
FY2019 Dec 31, 2018 $25.20M Mar 13, 2020
FY2018 Dec 31, 2017 $13.88M Mar 27, 2019
FY2017 Dec 31, 2016 $14.31M Mar 30, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $18.39M Mar 5, 2026
FY2025 Dec 31, 2024 $40.76M Mar 5, 2026
FY2025 Dec 31, 2023 $75.39M Mar 5, 2026
FY2024 Dec 31, 2022 $76.38M Mar 12, 2025
FY2023 Dec 31, 2021 $100.56M Feb 26, 2024
FY2022 Dec 31, 2020 $58.72M Mar 23, 2023
FY2021 Dec 31, 2019 $48.68M Mar 11, 2022
FY2020 Dec 31, 2018 $20.56M Mar 8, 2021
FY2019 Dec 31, 2017 $4.57M Mar 13, 2020
FY2018 Dec 31, 2016 $3.06M Mar 27, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $0 Mar 5, 2026
FY2025 Dec 31, 2024 $11.05M Mar 5, 2026
FY2025 Dec 31, 2023 $35.04M Mar 5, 2026
FY2023 Dec 31, 2022 $35.04M Feb 26, 2024
FY2022 Dec 31, 2021 $35.04M Mar 23, 2023
FY2021 Dec 31, 2020 $12.27M Mar 11, 2022
FY2020 Dec 31, 2019 $7.80M Mar 8, 2021
FY2019 Dec 31, 2018 $3.69M Mar 13, 2020
FY2018 Dec 31, 2017 $3.69M Mar 27, 2019
FY2017 Dec 31, 2016 $3.69M Mar 30, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 ($354.65M) Mar 12, 2025
FY2024 Dec 31, 2023 ($305.95M) Mar 12, 2025
FY2023 Dec 31, 2022 ($281.55M) Feb 26, 2024
FY2022 Dec 31, 2021 ($252.27M) Mar 23, 2023
FY2021 Dec 31, 2020 ($221.23M) Mar 11, 2022
FY2020 Dec 31, 2019 ($225.40M) Mar 8, 2021
FY2019 Dec 31, 2018 ($236.09M) Mar 13, 2020
FY2018 Dec 31, 2017 ($232.93M) Mar 27, 2019
FY2017 Dec 31, 2016 ($226.23M) Mar 30, 2018
FY2016 Dec 31, 2015 ($210.89M) Mar 10, 2017

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.49M Mar 5, 2026
FY2025 Dec 31, 2024 $2.81M Mar 5, 2026
FY2024 Dec 31, 2023 $7.13M Mar 12, 2025
FY2023 Dec 31, 2022 $14.03M Feb 26, 2024
FY2022 Dec 31, 2021 $16.08M Mar 23, 2023
FY2021 Dec 31, 2020 $25.75M Mar 11, 2022
FY2020 Dec 31, 2019 $28.27M Mar 8, 2021
FY2019 Dec 31, 2018 $12.16M Mar 13, 2020
FY2018 Dec 31, 2017 $2.21M Mar 27, 2019
FY2017 Dec 31, 2016 $2.23M Mar 30, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2018 Dec 31, 2017 $3.80M Mar 27, 2019
FY2017 Dec 31, 2016 $2.60M Mar 30, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (1) Mar 5, 2026
FY2025 Dec 31, 2024 (3) Mar 5, 2026
FY2024 Dec 31, 2023 (3) Mar 12, 2025
FY2023 Dec 31, 2022 0 Feb 26, 2024
FY2022 Dec 31, 2021 0 Mar 23, 2023
FY2020 Dec 31, 2020 0 Mar 8, 2021
FY2020 Jun 30, 2020 0 Mar 8, 2021
FY2020 Mar 31, 2020 0 Mar 8, 2021
FY2020 Dec 31, 2019 0 Mar 8, 2021
FY2020 Sep 30, 2019 0 Mar 8, 2021

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (1) Mar 5, 2026
FY2025 Dec 31, 2024 (3) Mar 5, 2026
FY2024 Dec 31, 2023 (3) Mar 12, 2025
FY2023 Dec 31, 2022 0 Feb 26, 2024
FY2022 Dec 31, 2021 0 Mar 23, 2023
FY2020 Dec 31, 2020 0 Mar 8, 2021
FY2020 Jun 30, 2020 0 Mar 8, 2021
FY2020 Mar 31, 2020 0 Mar 8, 2021
FY2020 Dec 31, 2019 0 Mar 8, 2021
FY2020 Sep 30, 2019 0 Mar 8, 2021

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 25.80M Mar 5, 2026
FY2025 Dec 31, 2024 17.67M Mar 5, 2026
FY2024 Apr 11, 2024 9.60M Mar 12, 2025
FY2025 Apr 10, 2024 9.60M Mar 5, 2026
FY2025 Apr 9, 2024 76.80M Mar 5, 2026
FY2024 Dec 31, 2023 9.35M Mar 12, 2025
FY2023 Dec 31, 2022 56.20M Feb 26, 2024
FY2022 Dec 31, 2021 54.26M Mar 23, 2023
FY2021 Dec 31, 2020 41.23M Mar 11, 2022
FY2020 Dec 31, 2019 38.48M Mar 8, 2021